Table 1.

Adverse Events Due to EGFR-TKIs in FAERS From 2016 to 2018

	Total (N = 8,450)	Osimertinib (n = 2,454)	Osimertinib + Other TKIs (n = 160)	Other TKIs (n = 5,836)
Cardiac failure	120 (1.4)	57 (2.3)	1 (0.6)	62 (1.1)
Atrial fibrillation	64 (0.8)	30 (1.2)	1 (0.6)	33 (0.6)
QT prolongation	49 (0.6)	33 (1.3)	4 (2.5)	12 (0.2)
Myocardial infarction	46 (0.5)	16 (0.7)	0 (0.0)	30 (0.5)
Pericardial effusion	36 (0.4)	14 (0.6)	2 (1.3)	20 (0.3)
Total	315 (3.7)	150 (6.1)	8 (5.0)	157 (2.7)

Values are n (% of total in each treatment category).

EGFR-TKI = epidermal growth factor receptor–tyrosine kinase inhibitor; FAERS = U.S. Food and Drug Administration Adverse Events Reporting System.